Fintel reports that on January 6, 2026, Citigroup upgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Buy. Analyst Price Forecast Suggests 11.58% Upside As of December 22, 2025, the ...

Arvinas (NASDAQ:ARVN) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Octopus and other cephalopods are good at hiding themselves—and are inspiring cutting-edge technologies that may help us do the same. Cephalopods like the giant Pacific octopus (Enteroctopus dofleini) ...

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with ...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a ...